SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-21-176894
Filing Date
2021-05-28
Accepted
2021-05-28 16:00:43
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A d190030ddefa14a.htm DEFA14A 23555
2 GRAPHIC g190030nap1g1.jpg GRAPHIC 143464
3 GRAPHIC g190030nap2g1.jpg GRAPHIC 319416
4 GRAPHIC g190030nap3g1.jpg GRAPHIC 245570
5 GRAPHIC g190030nap4g1.jpg GRAPHIC 226989
6 GRAPHIC g190030nap5g1.jpg GRAPHIC 263743
7 GRAPHIC g190030nap6g1.jpg GRAPHIC 146289
  Complete submission text file 0001193125-21-176894.txt   1878533
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36548 | Film No.: 21979977
SIC: 2836 Biological Products, (No Diagnostic Substances)